Loading clinical trials...

Role of Glare and Spectral Filtering on Contrast Sensitivity: A Pilot Study | Clinical Trials | Clareo Health

COMPLETEDNA

Role of Glare and Spectral Filtering on Contrast Sensitivity: A Pilot Study

NCT05582304•Johnson & Johnson Vision Care, Inc.

Summary

This will be a split-plot design, randomized, parallel, double-masked feasibility study to evaluate the role of a test lens on contrast sensitivity with and without glare.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Potential subjects must satisfy all of the following criteria to be enrolled in the study:
•The subject must:
•1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
•2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
•3. Be between 18 and 65 (inclusive) years of age at the time of screening.
•4. By self-report, habitually wear spherical silicone hydrogel soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.
•5. Possess a wearable pair of spectacles that provide correction for distance vision.
•6. The spherical equivalent of the subject's vertex corrected distance refraction must be between -1.00 D and -6.00 D (inclusive) in each eye.
•7. The magnitude of the cylindrical component of the subject's vertex-corrected distance refraction must be between 0.00 D and 1.00 D (inclusive) in each eye.
•8. The best corrected, monocular, distance visual acuity must be 20/25 or better in each eye.

Exclusion Criteria

•Potential subjects who meet any of the following criteria will be excluded from participating in the study:
•The subject must not:
•1. Be currently pregnant or lactating.
•2. Be currently using any ocular medications or have any ocular infection of any type.
•3. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication the investigator believes might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus \[HIV\]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
•4. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
•5. Be currently wearing monovision or multifocal contact lenses.
•6. Be currently wearing lenses in an extended wear modality.
•7. Have participated in a contact lens or lens care product clinical trial within 30 days prior to study enrollment.
•8. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
+6 more criteria

Locations (1)

University of Georgia

Athens, Georgia, United States

Key Dates

Start Date

October 31, 2022

Primary Completion Date

December 8, 2022

Completion Date

December 8, 2022

Last Updated

January 31, 2024

Enrollment

ACTUAL participants

Conditions

Visual Acuity

Interventions

Test Lens

DEVICE

Control Lens

DEVICE

Effect of Action Video Games and Stroboscopic Glasses on Dynamic Visual Acuity.

NCT05956938

Visual Acuity

View study

COMPLETEDNA

Evaluating ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management

NCT05634408

Visual Acuity

View study

NOT_YET_RECRUITING

Assessing the Turkish DDIVAT for Visual Acuity Measurement

NCT07240480

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Role of Glare and Spectral Filtering on Contrast Sensitivity: A Pilot Study

Inclusion Criteria

Exclusion Criteria

Effect of Action Video Games and Stroboscopic Glasses on Dynamic Visual Acuity.

Evaluating ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management

Assessing the Turkish DDIVAT for Visual Acuity Measurement

Evaluation of a Digital Visual Acuity Device vs. Standard Visual Acuity Measurements

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

Project ICOPE Brazil: Assessment of Intrinsic Capacity in Brazilian Older Adults